247 related articles for article (PubMed ID: 18538603)
1. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.
McVie-Wylie AJ; Lee KL; Qiu H; Jin X; Do H; Gotschall R; Thurberg BL; Rogers C; Raben N; O'Callaghan M; Canfield W; Andrews L; McPherson JM; Mattaliano RJ
Mol Genet Metab; 2008 Aug; 94(4):448-455. PubMed ID: 18538603
[TBL] [Abstract][Full Text] [Related]
2. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
[TBL] [Abstract][Full Text] [Related]
3. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
Zhu Y; Li X; McVie-Wylie A; Jiang C; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
Biochem J; 2005 Aug; 389(Pt 3):619-28. PubMed ID: 15839836
[TBL] [Abstract][Full Text] [Related]
4. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
[TBL] [Abstract][Full Text] [Related]
5. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease.
Zhu Y; Jiang JL; Gumlaw NK; Zhang J; Bercury SD; Ziegler RJ; Lee K; Kudo M; Canfield WM; Edmunds T; Jiang C; Mattaliano RJ; Cheng SH
Mol Ther; 2009 Jun; 17(6):954-63. PubMed ID: 19277015
[TBL] [Abstract][Full Text] [Related]
6. Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid α-glucosidase.
Basile I; Da Silva A; El Cheikh K; Godefroy A; Daurat M; Harmois A; Perez M; Caillaud C; Charbonné HV; Pau B; Gary-Bobo M; Morère A; Garcia M; Maynadier M
J Control Release; 2018 Jan; 269():15-23. PubMed ID: 29108866
[TBL] [Abstract][Full Text] [Related]
7. The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.
Khanna R; Flanagan JJ; Feng J; Soska R; Frascella M; Pellegrino LJ; Lun Y; Guillen D; Lockhart DJ; Valenzano KJ
PLoS One; 2012; 7(7):e40776. PubMed ID: 22815812
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts.
Yang HW; Kikuchi T; Hagiwara Y; Mizutani M; Chen YT; Van Hove JL
Pediatr Res; 1998 Mar; 43(3):374-80. PubMed ID: 9505277
[TBL] [Abstract][Full Text] [Related]
9. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
Martiniuk F; Chen A; Donnabella V; Arvanitopoulos E; Slonim AE; Raben N; Plotz P; Rom WN
Biochem Biophys Res Commun; 2000 Oct; 276(3):917-23. PubMed ID: 11027569
[TBL] [Abstract][Full Text] [Related]
10. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
[TBL] [Abstract][Full Text] [Related]
11. Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice.
Zhu Y; Li X; Kyazike J; Zhou Q; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
J Biol Chem; 2004 Nov; 279(48):50336-41. PubMed ID: 15383547
[TBL] [Abstract][Full Text] [Related]
12. Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease.
Hintze S; Limmer S; Dabrowska-Schlepp P; Berg B; Krieghoff N; Busch A; Schaaf A; Meinke P; Schoser B
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290314
[TBL] [Abstract][Full Text] [Related]
13. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease.
Fukuda T; Ahearn M; Roberts A; Mattaliano RJ; Zaal K; Ralston E; Plotz PH; Raben N
Mol Ther; 2006 Dec; 14(6):831-9. PubMed ID: 17008131
[TBL] [Abstract][Full Text] [Related]
14. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.
Pauly DF; Fraites TJ; Toma C; Bayes HS; Huie ML; Hirschhorn R; Plotz PH; Raben N; Kessler PD; Byrne BJ
Hum Gene Ther; 2001 Mar; 12(5):527-38. PubMed ID: 11268285
[TBL] [Abstract][Full Text] [Related]
15. Improved efficacy of a next-generation ERT in murine Pompe disease.
Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
[TBL] [Abstract][Full Text] [Related]
16. Production of recombinant human acid α-glucosidase with high-mannose glycans in gnt1 rice for the treatment of Pompe disease.
Jung JW; Huy NX; Kim HB; Kim NS; Van Giap D; Yang MS
J Biotechnol; 2017 May; 249():42-50. PubMed ID: 28363873
[TBL] [Abstract][Full Text] [Related]
17. Glycosylation-independent lysosomal targeting of acid α-glucosidase enhances muscle glycogen clearance in pompe mice.
Maga JA; Zhou J; Kambampati R; Peng S; Wang X; Bohnsack RN; Thomm A; Golata S; Tom P; Dahms NM; Byrne BJ; LeBowitz JH
J Biol Chem; 2013 Jan; 288(3):1428-38. PubMed ID: 23188827
[TBL] [Abstract][Full Text] [Related]
18. β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Koeberl DD; Li S; Dai J; Thurberg BL; Bali D; Kishnani PS
Mol Genet Metab; 2012 Feb; 105(2):221-7. PubMed ID: 22154081
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial.
Amalfitano A; Bengur AR; Morse RP; Majure JM; Case LE; Veerling DL; Mackey J; Kishnani P; Smith W; McVie-Wylie A; Sullivan JA; Hoganson GE; Phillips JA; Schaefer GB; Charrow J; Ware RE; Bossen EH; Chen YT
Genet Med; 2001; 3(2):132-8. PubMed ID: 11286229
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease.
Farah BL; Madden L; Li S; Nance S; Bird A; Bursac N; Yen PM; Young SP; Koeberl DD
FASEB J; 2014 May; 28(5):2272-80. PubMed ID: 24448824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
